carbazilquinone has been researched along with Lymphoma, B-Cell, Marginal Zone in 1 studies
Carbazilquinone: An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.
Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takenaka, T | 1 |
| Maruyama, K | 1 |
| Kinoshita, T | 1 |
| Sasako, M | 1 |
| Sano, T | 1 |
| Katai, H | 1 |
| Matsuno, Y | 1 |
1 trial available for carbazilquinone and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
A prospective study of surgery and adjuvant chemotherapy for primary gastric lymphoma stage II.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Che | 1997 |